Skip to main content
Log in

Optimal Sequencing of Anti-HER2 Therapy Throughout the Continuum of HER2-Positive Breast Cancer: Evidence and Clinical Considerations

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

With the advent of the monoclonal antibody trastuzumab over 2 decades ago for breast cancer therapy, the outcome of patients with human epidermal growth factor receptor (HER) 2-positive disease has improved dramatically. Based on its substantial efficacy and good tolerability, trastuzumab has become the therapeutic gold standard for early as well as advanced breast cancer. Nevertheless, despite adjuvant trastuzumab, patients do experience recurrence and require further anti-HER2-targeted therapy. Next to the small molecule tyrosine kinase inhibitor lapatinib, which was the first approved therapy option after trastuzumab failure, several new anti-HER2 agents are currently already available for clinical use [i.e. pertuzumab, T-DM1 (trastuzumab emtansine)] or are still being evaluated (e.g. afatinib, neratinib). Recent evidence from neoadjuvant as well as metastatic therapy suggests that dual blockade may be superior to single-agent HER2 blockade. While the number of available or potential therapies has increased considerably, no additional predictive biomarkers beyond HER2 have been validated for the use of the different anti-HER2 therapies. Moreover, novel therapeutic concepts such as the antibody-drug conjugate T-DM1 warrant excellent determination methodology for HER2 and suggest re-evaluation of tumor biology upon first metastasis. The clinical challenge remains to optimally choose, utilize, and sequence anti-HER2 therapy in early as well as metastatic breast cancer. This article will provide evidence-based guidance for sequencing anti-HER2 therapy throughout the continuum of breast cancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Perou CM, et al. Molecular portraits of human breast tumors. Nature. 2000;406(6797):747–52.

    Article  PubMed  CAS  Google Scholar 

  2. Sorlie T, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418–84233.

    Article  PubMed  CAS  Google Scholar 

  3. The Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.

    Google Scholar 

  4. Hammond ME, Hayes DF, Wolff AC. Clinical notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol. 2011;29(15):e458.

    Article  PubMed  Google Scholar 

  5. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagy GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2-therapy as personalized medicine. Oncologist. 2009;14(4):320–68.

    Article  PubMed  CAS  Google Scholar 

  6. Cuzick J, Dowsett M, Wale C, et al. Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score—results from TransATAC. Cancer Res. 2009;69(Suppl).

  7. Paik S, Liu ET. HER2 as a predictor of therapeutic response in breast cancer. Breast Dis. 2000;11:91–102.

    PubMed  CAS  Google Scholar 

  8. Di Leo A, Chan S, Paesmans M, et al. HER-2/neu as a predictive marker in population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat. 2004;86(3):197–206.

    Article  PubMed  Google Scholar 

  9. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89(10):4285–9.

    Article  PubMed  CAS  Google Scholar 

  10. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16(8):2659–71.

    PubMed  CAS  Google Scholar 

  11. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N Eng J Med. 2001;344:783–92.

    Article  CAS  Google Scholar 

  12. Piccart-Gebhart MJ. Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn. Eur J Cancer. 2006;42(12):1715–9.

    Article  PubMed  CAS  Google Scholar 

  13. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.

    Article  PubMed  CAS  Google Scholar 

  14. AGO recommendations 2012 for diagnosis and treatment of early and metastatic breast cancer. http://www.ago-online.de.

  15. Gnant M, Harbeck N, Thomssen C. St. Gallen 2011: summary of the consensus discussion. Breast Care. 2011;6(2):136–41.

    Article  PubMed  Google Scholar 

  16. NCCN National Comprehensive Cancer Network, USA. http://www.nccn.org.

  17. Ismael G, Hegg R, Muehlbauer S. Heinzmann D, Lum B, Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13(9):869–78.

    Google Scholar 

  18. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 overexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008;26:1642–9.

    Article  PubMed  CAS  Google Scholar 

  19. Bria E, Cuppone F. Fornier M et al Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat. 2008;109:231–9.

    Article  PubMed  CAS  Google Scholar 

  20. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3355–73.

    Article  Google Scholar 

  21. Harbeck N, Ewer MS, De Laurentiis M, Suter TM, Ewer SM. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Ann Oncol. 2011;22(6):1250–8.

    Article  PubMed  CAS  Google Scholar 

  22. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F, ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii155–66.

    Google Scholar 

  23. Amir E, Orcano A, Seruga B, Freedman O, Clemons M. Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer. Cancer Treat Rev. 2010;36(5)410–5.

    Google Scholar 

  24. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, et al. Phase III, double-blind, randomizes study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008;26:5544–52.

    Article  PubMed  Google Scholar 

  25. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83:679–86.

    PubMed  Google Scholar 

  26. Baselga J, Swain S. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab in HER2-positive metastatic breast cancer. Clin Breast Cancer. 2010;10(6):489–91.

    Article  PubMed  Google Scholar 

  27. Lorusso PM, Weiss D, Guardino E, Grish S, Shwkowski MX. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal-growth factor receptor 2-positive cancer. Clin cancer Res. 2011;17:6437–47.

    Article  PubMed  CAS  Google Scholar 

  28. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER-2 antibody-drug conjugate, given every 3 weeks to patients with HER-2 positive metastatic breast cancer. J Clin Oncol. 2010;28:2698–704.

    Article  PubMed  CAS  Google Scholar 

  29. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, The EMILIA study group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.

    Google Scholar 

  30. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011;29(34):4491–7.

    Article  PubMed  CAS  Google Scholar 

  31. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Ointer T, Valero V, Liu MC, Sauter G, von Minckwith G, Visco F, Bee V, Buysse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–83.

    Article  PubMed  CAS  Google Scholar 

  32. Gonzalez-Anguelo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27(834):5700–6.

    Article  Google Scholar 

  33. Gelber RD, Goldhirsch A, Piccart M, Procter M, De Azambuja E, Weber H, Untch M, Smith IE, Gianni L, Jackisch C, Cameron D, Bell R, Dowsett M, Leyland-Jones B, Baselga J. HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up ESMO 2012, abstract LBA 6_PR.

  34. Pivot X, Romieu H, Bonnefoi H, Pierga JY, Kerbrat P, Guastalla JP, Lortholary A, Espié M, Fumoleau PC, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporte I, Kramar A. PHARE Trial results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. ESMO. 2012, abstract LBA 5_PR.

  35. Yin W, Jiang Y, Shen Z, Shao Z, Lu J. Trastuzumab in the adjuvant treatment of HER-2 positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PloS. 2011;6(6):e21030.

    Article  CAS  Google Scholar 

  36. Verma Su, Lavasani S, Mackey J, Pritchard K, Clemons M, Dent S, Latreille J, Lemieux J, Provencher L, Verma Sh, Chia S, Wang B, Rayson D. Optimizing the management of HER2-positive early breast cancer: the clinical reality. Curr Oncol. 2010;17(4):154–67.

    Article  Google Scholar 

  37. Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favourable survival in human epidermal growth factor receptor 2-overexpression breast cancer. Results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29(25):3341–7.

    Article  Google Scholar 

  38. Gianni L, Dafni U, Gelber RD, Azambuje E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, JKackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccaret-Gebhardt MJ, Bell R. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12(3):236–44.

    Google Scholar 

  39. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633–40.

    Article  PubMed  CAS  Google Scholar 

  40. Robidoux A, Tang G, Rastogi P, Geyer CE, Azar CA Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Kuebler JP, Margolese RG, Farrar WB, Brufsky A, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41J. Clin Oncol. 2012;30(suppl):abstr LBA506.

  41. Gianni L, Pienkowski T, Im YH, roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, dela Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere). A randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.

    Google Scholar 

  42. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo J-H, Tsai Y-F, Ackrill A, Ross G, Cortés J. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA). Cancer Res. 2011;71(24 Suppl.):112s, S5-6.

    Google Scholar 

  43. Valachis A, Nearchou A, Lind P, Mauri D. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer. A meta-analysis of randomized evidence. Breast Cancer Res Treat. 2012;135(83):655–662.

    Google Scholar 

  44. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo J-H, Tsai Y-F, Ackrill A, Ross G, Cortés J. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA). Cancer Res. 2011;71(24 Suppl.):S5–6.

    Google Scholar 

  45. Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013;31(14):1726–31.

    Google Scholar 

  46. Pestalozzi B, Holmes E, Metzger O, de Azambuja E, Hogge L, Scullion M, Gelber R, Piccart-Gebhart M, Cameron D, HERA Study Team. Trastuzumab does not increase the incidence of central nervous system (CNS) relapses in HER2-positive early breast cancer: the HERA trial experience. Cancer Res. 2011;71(24 Suppl.):P4-17-01.

  47. Dawood S, Gong Y, Broglio K, Buchholz TA, Woodward W, Lucci A, Valero V, Gonzalez-Angulo AM, Hortobagy GN, Cristofanili M. Trastuzumab in primary inflammatory breast cancer (IBC): high pathological response rates and improved outcome. Breast J. 2010.

  48. Kennecke H, Yerushalmi R, Wood R, et al. Metastatic behaviour of breast cancer subtypes. J Clin Oncol. 2010;28:3271–7.

    Article  PubMed  Google Scholar 

  49. Thomssen C, Marschner N, Untch M, et al. ABC1 consensus conference—a German perspective: first international consensus conference on advanced breast cancer (ABC1), Lisbon, November 5, 2011. Breast Care. 2012;7(1):52–9.

    Article  PubMed  Google Scholar 

  50. Khasraw M, Brogi E, Seidman AD. The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? Curr Oncol Rep. 2011;13(1):17–25.

    Article  PubMed  Google Scholar 

  51. Wilking U, Karlsson E, Skoog L, et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat. 2011;125(2):553–61.

    Article  PubMed  CAS  Google Scholar 

  52. Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012;30(6):587–92.

    Article  PubMed  Google Scholar 

  53. Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30(21):2601–8.

    Article  PubMed  Google Scholar 

  54. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28(1):92–8.

    Article  PubMed  CAS  Google Scholar 

  55. Dawood S, Sesetkova E, Gonzales-Angulo AM. Trastuzumab administration associated with change in HER 2 status. Clin Breast Cancer. 2008;8(4):366–9.

    Article  PubMed  Google Scholar 

  56. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Peinkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al. Laptinib plus capecitabine for HER-2 positive advanced breast cancer. N Engl J Med. 2006;355:2733–43.

    Article  PubMed  CAS  Google Scholar 

  57. Goel S, Chirgwin J, Francis P, Stuart-Harris R, Dewar J, Milshkin L, Snyder R, Michael M, Koczwara B. Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications and recent research. Breast. 2011;20(2):p101–10.

    Article  Google Scholar 

  58. Kaufmann B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor-2 positive metastatic breast cancer: results from the randomized phase III TanDEM study. J Clin Oncol. 2009;27:5529–37.

    Article  Google Scholar 

  59. Huober HJ, von Minckwitz G. Neoadjvant therapy—what have we achieved in the last 20 years? Breast Care. 2011;6:419–26.

    Article  PubMed  Google Scholar 

  60. Anderson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor-2 positive breast cancer. J Clin Oncol. 2011;29:264–71.

    Article  Google Scholar 

  61. Koeberle D, Ruhstaller T, Jost L, Pagani O, Zaman K, von Moos R, Oehlschlegel C, Crowe S, Pilop C, Thuerlimann B. Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2 positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Endocrine-Related Cancer. 2011;V18, N2, APR:257–64.

    Google Scholar 

  62. Hamberg P, Bos M, Braun H, Stouthard J, van Deijk G, Erdkamp F, van der Stelt-Frissen I, Bontenbal M, Creemers GJ, Portielje J, Pruijt J, Loosveld O, Smit W, Muller E, Schmitz P, Seynaeve C, Klijn J. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER-2 positive metastatic breast cancer: HERTAX trial. Clin Breast Cancer. 2011;V11, N2, APR:103–13.

  63. Steger G, Bartsch R. Trends and novel approaches in neoadjuvant treatment of breast cancer. Breast Care. 2011;6:427–33.

    Article  PubMed  Google Scholar 

  64. Von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor-2 positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol. 2009;27:1999–2006.

    Article  Google Scholar 

  65. Von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stsein RC, Nekljudova V, Loibl S. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011;47(15):2273–81.

    Article  Google Scholar 

  66. Baselga J, Cortes J, Sung-Bae K, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19.

    Article  PubMed  CAS  Google Scholar 

  67. Swain SM, Kim S-B, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–71.

    Article  PubMed  CAS  Google Scholar 

  68. Baselga J, Cortés J, Im S-A, Clark E, Kiermaier A, Ross G, Swain SM. Biomarker analyses in CLEOPATRA: a phase III, placebocontrolled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Cancer Res. 2012;72(24 Suppl.):S5-1.

    Google Scholar 

  69. Cortes J, Roche H. Docetaxel combined with targeted therapies in metastatic breast cancer. Cancer Treat Rev. 2012;38(5):387–96.

    Article  PubMed  CAS  Google Scholar 

  70. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P. Gianni L Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28(7):1138–44.

    Article  PubMed  CAS  Google Scholar 

  71. Burris HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2/HER2-)positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29:398–405.

    Article  PubMed  CAS  Google Scholar 

  72. Krop IE, Lorusso P, Miller KD, Modi S, Yardley D, Rodriduez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP. Rugo HS A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane and capecitabine. J Clin Oncol. 2012;30(26):3234–41.

    Article  PubMed  CAS  Google Scholar 

  73. Mathew J. Perez EA Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer. A review. Curr Opin Oncol. 2011;23(6):594–600.

    Article  PubMed  CAS  Google Scholar 

  74. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112:533–43.

    Article  PubMed  CAS  Google Scholar 

  75. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, et al. Phase III trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;26:1993–9.

    Article  PubMed  CAS  Google Scholar 

  76. Pivot X. Semiglazov V, Żurawski B, Allerton R, Fabi A, Ciruelos E, Parikh R, Desilvio M, Santillana S, Swaby R. CEREBEL (EGF111438): An open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2 + Metastatic Breast Cancer (MBC), treated with Lapatinib plus Capecitabine (LC) versus Trastuzumab plus Capecitabine (TC). ESMO. 2012, LBA11.

  77. Johnston S, Pegram M, Press M, Pippen J, Pivot X, Gomez H, Florance A, O’Rourke L, Maltzman J. Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial. Cancer Res. 2008;69:46.

    Article  Google Scholar 

  78. Gelmon KA, Boyle F, Kaufman B, Huntsman D, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Dent SF, Ellard S, Tonkin KS, Nagarwala YM, Pritchard KI, Whelan TJ, Nomikos D, Chapman JAW, Parulekar W. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. ASCO. 2012, LBA671.

  79. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, Ng C, Franco SX, Chow LW, Arbushites MC, Casey MA, Berger MS, Stein SH, Sledge GW. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 2008;26(18):2999–3005.

    Article  PubMed  CAS  Google Scholar 

  80. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with erbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28:1124–30.

    Article  PubMed  CAS  Google Scholar 

  81. Blackwell KL, Burstein HJ, Storniolo AM, Rugos HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O`Shaughnessy J. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol. 2012;30(21):2585–92.

    Article  PubMed  CAS  Google Scholar 

  82. Ahn E, Vogel C. Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat. 2012;131:371–83.

    Article  PubMed  Google Scholar 

  83. Fleeman N, Bagust A, Boland A, Dickson R, Dundar Y, Moonan M, Oyee J, Blundell M, Davis H, Armstrong A, Thorp N. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive brast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. Health Technol Assess. 2011;15(42):1–93, iii–iv.

    Google Scholar 

  84. Huober J, Fasching PA, Barsoum M, Petruzelka L, Wallwiener D, Thomssen C, Reimer T, Paepke S, Azim HA, Ragosch V, Kubista E, Baumgärtner AK, Beckmann MW, May C, Nimmrich I, Harbeck N. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer—results of the eLEcTRA trial. Breast. 2012;21(1):27–33.

    Article  PubMed  CAS  Google Scholar 

  85. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265–74.

    Article  PubMed  CAS  Google Scholar 

  86. Cameron D, Casey M, Oliva C, et al. Lapatinib plus capecitabine in women with HER-2 positive advanced breast cancer. Final survival analysis of a phase III randomized trial. Oncologist. 2010;15(9):924–34.

    Article  PubMed  CAS  Google Scholar 

  87. Harris C, Ward R, Dobbins T, Drew A, Pearson S. The efficacy of HER2-targeted agents in metastatic breast cancer. A meta-analysis. Ann Oncol. 2011;22:1308–17.

    Article  PubMed  CAS  Google Scholar 

  88. Solca FF, Adolf G, Jones H, Uttenreuther-Fischer M. Drugs for HER-2 positive breast cancer. Milestones Drug Therapy. 2011. doi:10.1007/978-3-0346-0094-16.

  89. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27:4702–11.

    Article  PubMed  CAS  Google Scholar 

  90. Minkovsky N, Berezov A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs. 2008;9:1336–46.

    PubMed  CAS  Google Scholar 

  91. Schuler M, Awada A, Harter P, et al. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2012;134(3):1149–59.

    Article  PubMed  CAS  Google Scholar 

  92. Lin NU, Wiener EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T. A phase II study of afatinib (BIBW 2992), an irreversible Erb B family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat. 2012;133(3):1057–65.

    Article  PubMed  CAS  Google Scholar 

  93. Lopez-Tarruella S, Jerez Y, Marquez-Rodas I, Martin M. Neratinib (HKI-272) in the treatment of breast cancer. Future Oncol. 2012;8(6):671–81.

    Article  PubMed  CAS  Google Scholar 

  94. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010;28(8):1301–7.

    Article  PubMed  CAS  Google Scholar 

  95. Awada A, Dirix L, Manso Sanchez L, Xu B, Luu T, Dieras V, Hershman DL, Agrapart V, Ananthakrishnan R, Staroslawska E. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2-therapy. Ann Oncol. 2013;24(1):109–16.

    Google Scholar 

  96. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nunez R, Hortobagyi GN, Yu D, Esteva FJ. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol. 2011;29(23):3126–32.

    Article  PubMed  CAS  Google Scholar 

  97. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D. Hortobagyi GN Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med. 2012;366(6):520–9.

    CAS  Google Scholar 

  98. O’Regan R, Ozguroglu M, Andre F, Toi M, Jerusalem GHM, Wilks S, Isaacs C, Xu B, Masuda N, Arena FP, Yardley DA, Yap YS, Mukhopadhyay P, Douma S, El-Hashimy M, Taran T, Sahmoud T, Lebwohl DE, Gianni L. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). J Clin Oncol. 2013;31(suppl):abstr 505.

  99. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res. 2004;10(5):1706–16.

    Article  PubMed  CAS  Google Scholar 

  100. Rugo H, Chien S, Franco S, Stopeck A, Glenvcer A, Lahiri S, Arbushites M, Scott J, park J, Hudis V, Nulsen B, Dickler M. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2012;134(1):13–20.

  101. Hurvitz SA, Pegram MD, Lin L-S, et al. Final results of a phase II trial evaluating trastuzumab and bevacizimab as first line treatment of HER2-amplified. Adv Breast Cancer SABCS. 2009, abstract 6094.

  102. Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V. AVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013;31(14):1719–25.

    Google Scholar 

  103. Konecny GE, Pegram MD, Venkatesan N, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, et al. Activity of dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66:1630–9.

    Article  PubMed  CAS  Google Scholar 

  104. Rimm D, Ballman KV, Cheng H, Vassilakopoulou M, Chen B, Gralow J, Hudis C, Davidson NE, Psyrri A, Fountzilas G, Perez EA. EGFR expression measured by quantitative immunofluorescense is associated with decreased benefit from trastuzumab in the adjuvant setting in the NCCTG (Alliance) N9831 trial. Cancer Res. 2012;72(24 Suppl.):S5-4.

    Google Scholar 

  105. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii11–9.

    Google Scholar 

  106. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, van’t Veer L, Viale G, Krop I, Winer E. 1st International Consensus Guidelines for Advanced Breast Cancer (ABC 1). Breast. 2012;21(3):242–52.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

Nadia Harbeck: honoraria for consulting/lectures: Roche, Novartis, GSK.

Rachel Wuerstlein: honoraria for consulting/lectures: Roche, Novartis, GSK, Boehringer Ingelheim.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nadia Harbeck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harbeck, N., Wuerstlein, R. Optimal Sequencing of Anti-HER2 Therapy Throughout the Continuum of HER2-Positive Breast Cancer: Evidence and Clinical Considerations. Drugs 73, 1665–1680 (2013). https://doi.org/10.1007/s40265-013-0118-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-013-0118-z

Keywords

Navigation